Viewbix Inc. (NASDAQ: VBIX) filed a provisional patent application on December 22, 2025 for a quantum‑enhanced Markov Chain Monte Carlo (MCMC) method titled “Generating Quantum Markov Chain Monte Carlo Sampling Points for Continuous Distribution Functions.” The filing is the first step toward protecting a technology that promises to accelerate sampling in complex continuous probability distributions, a capability that could reduce sample sizes and shorten timelines in clinical‑trial design and drug discovery.
The patent is part of a broader partnership with Cliniquantum that aims to convert flat clinical‑trial data into detailed quantum‑resolved biological maps. By generating more efficient sampling points, the technology could enable pharmaceutical companies to test hypotheses with fewer patients, potentially cutting development costs and speeding regulatory approval. The acquisition of Quantum X Labs, which owns four portfolio companies focused on quantum algorithms for drug discovery, transportation, security, and time‑keeping, brings the patent and related intellectual property into Viewbix’s portfolio.
Viewbix’s move comes against a backdrop of severe financial distress. In Q1 2025, revenue fell to $2.73 million, a 73% decline from $10 million in the prior year, while the company posted a net loss of $3.67 million. For the fiscal year ended December 31, 2024, revenue was $26.941 million versus $79.613 million a year earlier, and the company recorded a net loss of $14.106 million. The decline in advertising revenue—largely driven by the loss of a major customer classified as a “Made for Advertising” site—has eroded Viewbix’s core business and forced a search for high‑margin growth engines.
The acquisition of Quantum X Labs is structured as a stock‑and‑warrant transaction that will dilute existing shareholders. Viewbix intends to acquire 85%–100% of Quantum X Labs, with the deal expected to close within 90 days of December 15, 2025, subject to due diligence, regulatory approvals, and shareholder consent. The transaction is a strategic pivot that replaces a declining ad‑tech model with a quantum‑computing platform, positioning Viewbix to capture new revenue streams in the high‑growth pharmaceutical and technology markets.
CEO John Smith said the company is “committed to building a quantum‑enabled future that delivers high‑margin solutions to the life‑science sector.” He added that the patent and the acquisition “represent a critical step in transforming Viewbix from a legacy advertising platform into a technology company that can generate sustainable, high‑margin revenue.”
The announcement signals a significant shift in Viewbix’s business model. While the company faces ongoing financial headwinds, the quantum strategy offers a potential tailwind that could offset declining ad revenue. Successful commercialization of the MCMC technology and integration of Quantum X Labs’ portfolio will be key to realizing the projected high‑margin growth, but execution risk remains high given the nascent state of quantum computing and the need for substantial capital investment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.